Korean Post-marketing Surveillance for Xeljanz

NCT02984020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1041

Last updated 2024-08-27

Study results available
· View outcomes & findings →

Summary

The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-13
Primary Completion
2022-06-09
Completion
2022-06-09

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02984020 on ClinicalTrials.gov